NFKB1 and autoimmune disease: SCFAs have been reported to promote the development of some autoimmune diseases, enhance interleukin-10 (IL-10) release, activate Treg cells, inhibit the production of proinflammatory cytokines, such as NF-kB, and alleviate colonic inflammation47,48.